Brand Intelligence Graphcompany
Company Overview
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
Business Model & Competitive Advantage
The company operates a dual business model combining internal drug pipeline development with external platform licensing and partnerships. Insilico has secured major collaboration deals valued at billions of dollars with partners including Eli Lilly, Sanofi, Fosun Pharma, Exelixis, and Menarini. Its competitive edge lies in an end-to-end AI platform covering target discovery through clinical candidate nomination, significantly compressing traditional drug development timelines and costs.
Competitive Landscape 2025–2026
Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, in the largest biotech IPO on HKEX that year, raising $293M. In March 2026, the company signed a landmark $2.75B agreement with Eli Lilly including a $115M upfront payment. Total 2025 revenue reached $56.2M. With over $393M in cash post-IPO and a robust partnership portfolio valued at over $3.5B collectively, Insilico is positioned as a leading AI-native pharma company.
Key Differentiators
Strong Challenger
Insilico Medicine is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Insilico Medicine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Insilico Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Insilico Medicine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Insilico Medicine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →